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Abstract
Many scientists have expended efforts to determine what regulates de-
velopment of an indifferent gonad into either a testis or ovary. Expres-
sion of Sry and upregulation of Sox9 are factors that initiate formation 
of the testis-specific pathway to allow for both sex-specific vasculature 
and seminiferous cord formation. Migration of mesonephric precur-
sors of peritubular myoid cells and endothelial cells into the differen-
tiating testis is a critical step in formation of both of these structures. 
Furthermore, these events appear to be initiated downstream from Sry 
expression. Sertoli cell secretion of growth factors acts to attract these 
mesonephric cells. One hypothesis is that a growth factor specific for 
these cell linages act in concert to coordinate migration of both peritu-
bular and endothelial cells. A second hypothesis is that several growth 
factors stimulate migration and differentiation of mesonephric “stem-
like” cells to result in migration and differentiation into several dif-
ferent cell lineages. While the specific mechanism is unclear, several 
growth factors have been implicated in the initiation of mesonephric 
cell migration. This review will focus on the proposed mechanisms of 
a growth factor, Vascular Endothelial Growth Factor, and how differ-
ent angiogenic and inhibitory isoforms from this single gene may aid 
in development of testis-specific vascular development.
      
Introduction
Why study gonadal differentiation and sex-specific vascular 
development?
Infertility affects 40–70 million couples; of those approx-
imately 50% of the infertility problems are attributed to 
male-related factors which include: low sperm count, ab-
normal spermatogenesis, and reduced androgen produc-
tion (Skakkebaek 2004). In the past 12 years, the incidence 
of male infertility cases has increased at an alarming rate 
resulting in the development of a new syndrome—testic-
ular dysgenesis syndrome. The reasons for the increase in 
testicular abnormalities are not understood but may be a 
result of genetic or environmental disruption of cell differ-
entiation during testis morphogenesis (Skakkebaek 2004). 
Formation of testicular cords, and sex-specific vasculature, 
are the two morphological hallmarks that distinguish a tes-
tis from an ovary. Testis development is initiated by Sertoli 
cell differentiation and expression of Sry, causing meso-
nephric cell migration into the differentiating testis to form 
seminiferous cords. Removal of the mesonephros or block-
age of mesonephric cell migration prevents cord formation. 
Thus, the migration of mesonephric derived cells, which 
include pre-endothelial and pre-peritubular cells, are crit-
ical to testis development.
What is known about embryonic testis morphogenesis?
In the mouse, the Sry gene is expressed in embryos at 
10.5 days post-coitus (dpc) and ceases after 12.5 dpc. Sry 
induces expression of genes which cause differentiation of 
the Sertoli cell lineage from precursor somatic cells in the 
coelomic epithelium (Figure 1) (Cupp and Skinner 2005). 
So even though Sry function is important, expression in the 
rodent is brief. The Sertoli cell is the first cell of the testis 
to differentiate (Magre and Jost 1991). After differentiation, 
Sertoli cells begin to proliferate and simultaneously move 
into the gonad proper, forming aggregates with primordial 
germ cells. Proliferation of Sertoli cells increases the size of 
the testis, and this proliferation appears to be solely depen-
dent on the expression of Sry (Schmahl et al. 2000). Without 
differentiation and proliferation of the Sertoli cells, the in-
different gonad would not develop into a testis.
  After Sertoli cell differentiation, testicular cords and sex-
specific vasculature develop to establish adult testis mor-
phology. In the mouse, these events occur during 11.5–
12 dpc and are complete by 12.5 dpc while in the rat these 
events occur between embryonic day 13.5–14 (Martineau 
et al. 1997). Induction of cord formation is initiated by cell 
migration from the adjacent mesonephros into the devel-
oping testis to surround the primordial germ and Sertoli 
cell aggregates (Buehr et al. 1993; Merchant-Larios et al. 
1993). Mesonephric cell migration is the result of Sry reg-
ulated expression of paracrine growth factors secreted by 
Sertoli cells (Martineau et al. 1997). Paracrine growth fac-
tors act as chemo-attractants inducing mesonephric cell 
migration and cord formation (Ricci et al. 1999; Cupp et al. 
2000, 2002, 2003; Colvin et al. 2001). If mesonephric cell mi-
gration is blocked, or if the mesonephros is removed, no 
cords will form. The population of cells that migrate from 
the mesonephros is proposed to be pre-endothelial and/
or pre-peritubular cells (Buehr et al. 1993; Merchant-Larios 
et al. 1993). Therefore, in addition to surrounding the Ser-
toli-primordial germ cell aggregates to form testis cords, 
the migrating mesonephric cells may also initiate the for-
mation of vasculature within the developing testis. Plate-
let-derived growth factor (Uzumcu et al. 2002a) and VEGF 
(Bott et al. 2006) have been demonstrated to be necessary 
for cord formation; however, only VEGF has been dem-
onstrated to be critical for both vascular development and 
cord formation.
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Figure 1. Sry-regulated events occurring dur-
ing sex determination and testis morphogene-
sis using days post-coitum and tail somites as 
developmental markers (modified from Cupp 
and Skinner 2005) 
What is known about formation of sex-specific vascular 
development?
Very little is known about what regulates sex specific vas-
cular development in the gonads. Pre-endothelial cells 
in the indifferent gonad express markers for both veins 
(EphB4) and arteries (ephrin B2); however this changes as 
each gonad develops sex-specific structures. In the testis, 
endothelial cells migrate from the mesonephros and form 
vascular networks with arterial markers between cords 
and the coelomic vessel. The coelomic vessel is the major 
testicular artery that is formed when mesonephric endo-
thelial cells migrate from the mesonephros into the testis 
and is unique to the testis. As endothelial cells differenti-
ate a greater percentage develop into arteries and contrib-
ute to the coleomic vessel than those which contribute to 
veins within the testis. The development of arteries may 
be necessary to aid movement of testosterone to the devel-
oping male reproductive tract which allows for its mainte-
nance and differentiation (Brennan et al. 2002). In contrast, 
the ovary develops similar amounts of arterial and venous 
networks from endothelial cells.
The origin of vasculature is different in the testis and 
ovary with vascular networks developing through angio-
genesis (branching from existing vasculature in the meso-
nephros) in the testis and through vasculogenesis (de novo 
or neovascularization) in the ovary (Brennan et al. 2002). It 
is likely that the testis and ovary develop vascular patterns 
from different endothelial cell origins due to expression of 
sex-specific transcription factors. Furthermore, sex-specific 
transcription factors stimulate different growth factors to not 
only initate blood vessel formation but organ-specific sup-
port structures such as seminiferous cords or oogonial cysts.
Experiments using knockout mice demonstrate that dis-
ruption of vascular development also causes sex-reversal 
and abnormalities in germ cell development. Mice that are 
null for Wnt4 (Jeays-Ward et al. 2003) and Follistatin (Fst) 
(Yao et al. 2004) have sex-reversed XX gonads with ectopic 
expression of a coelomic vessel and vasculature surround-
ing seminiferous cord-like structures. The Wnt4 gene reg-
ulates expression of Fst so it is not surprising that mice 
null for both of these genes have the same phenotype. Fol-
listatin is only expressed in the XX gonad and in general 
acts to inhibit activins. Therefore, there is potential for ac-
tivins to be involved in formation of the coelomic vessel. 
In contrast Inhibin beta b (Inhbb) XY null mice do not form 
coelomic vessels 50% of the time. Thus, Inhbb null XY go-
nads are sometimes sex-reversed to XX vascular pheno-
types. Activin A is composed of two inhibin beta a, Inhba, 
subunits while Activin B is composed of two Inhbb sub-
units. In the ovary, only Inhbb is expressed and not Inhba. 
Furthermore, expression of Inhbb is fourfold higher in the 
testis compared to the ovary at 12.5 dpc. Mating of Wnt4 
and Inhbb null mice recapitulate the normal phenotype in 
XY gonads to form a coelomic vessel. Yet, matings between 
Inhbb and Fst null mice did not recapitulate the XY vascu-
lar phenotype, thus Wnt4 suppression of Inhbb appears to 
be independent of Fst inhibitory actions on activins (Jeays-
Ward et al. 2003; Yao et al. 2006).
During normal testis development, Sry antagonizes ex-
pression of Wnt4 to suppress Fst and relieve inhibition of 
Inhbb (Figure 2). We can only speculate that Inhbb tran-
scriptional regulation is due to expression of Sox-9, or other 
growth factors downstream of Sry expression. Inhbb stim-
ulates endothelial cell migration and formation of a coe-
lomic vessel. In XX gonads with no Wnt4 repression, Fst 
expression is increased and Inhbb expression is down reg-
ulated to prevent endothelial cell migration and formation 
of ovarian-specific vascular patterns (Yao et al. 2004).
  
Figure 2. Genes demonstrated to be involved in sex-specific 
vascular patterns through development of null mice or treat-
ment of indifferent gonads in organ culture 
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In addition to the potential actions of Activin B, XX go-
nads treated with bone morphogenic proteins (BMP), anti-
mullerian hormone (AMH) and Activin A in vitro devel-
oped a sex-reversed phenotype with formation of an ectopic 
coelomic vessel; however, AMH deficient mice did not de-
velop this same phenotype (Ross et al. 2003; Yao et al. 2004). 
Bone morphogenic protein, AMH, Activin A and Inhbb 
are members of the transforming growth factor-beta (TGF-
β) superfamily and directly regulate cell function through 
inhibition or activation of the SMAD signal transduction 
pathway. In the zebrafish, SMAD response elements in the 
promoter region of Vegfa gene also appear to regulate ex-
pression of different isoforms (He and Chen 2005). Thus, 
the Vegfa gene may be a downstream gene regulated by 
members of the TGF family to regulate sex-specific vascu-
lature in the developing gonad (Figure 2).
    
What is known about the vascular endothelial growth factor 
family?
The VEGF family is composed of five ligands: VEGF (VEGF-
A), VEGF-B, VEGF-C, VEGF-D and placenta growth factor. 
VEGF (VEGF-A) is the best characterized and most potent 
VEGF molecule. VEGF works through both Fms-like tyro-
sine kinase 1 (FLT1) and Kinase domain region receptor 
(KDR), to elicit its effects on endothelial cell migration, dif-
ferentiation, proliferation and survival and apoptosis. The 
primary receptor involved in neovascularization of organs 
with VEGF is KDR which contains a tyrosine kinase signal 
transduction domain (Waltenberger et al. 1994). There are 
conflicting reports about the role of FLT1 in regulation of 
VEGF’s actions. In Flt1 knockouts, the mice die due to vas-
culature overgrowth suggesting that FLT1 acts as a decoy 
receptor to inhibit VEGF-dependent vascular development. 
Furthermore, FLT1 can also inhibit VEGF’s actions by di-
merizing with KDR to inhibit signal transduction. Thus, 
FLT1 appears to act as a negative regulator of VEGF’s ac-
tions on endothelial cell migration, survival and prolifera-
tion (Ferrara 2000; Olsson et al. 2006).
Both mRNA and protein for VEGF and KDR are pres-
ent during testis morphogenesis and are expressed in cells, 
like the Sertoli cell, that direct testis development. How-
ever, Flt1 is not expressed until after cord formation in the 
testis (Bott et al. 2006). The absence of FLT1 during meso-
nephric endothelial cell migration and establishment of 
vasculature in the testis may allow for endothelial cell mi-
gration through VEGF. In contrast, the ovary, which does 
not have mesonephric cell migration, expresses both Flt1 
and Kdr during development (Pohlmann et al. 2004). Thus, 
VEGF angiogenic isoforms may be bound by FLT1 recep-
tor in the ovary inhibiting the ability of mesonephric en-
dothelial cells to be recruited into the developing ovary; 
thus providing a different endothelial cell origin for ovar-
ian vasculature.
Vascular endothelial growth factor is transcribed from a 
single gene that has eight exons and is alternatively spliced 
into different isoforms each containing a different number 
of amino acids. The most common angiogenic isoforms are 
VEGF205, 188, 164, 144 and 120 (in humans the angiogenic 
isoforms are one amino acid longer; Figure 3). The predom-
inant isoforms expressed in tissues are VEGF188, 164 and 
120 (Veikkola and Alitalo 1999).
  In 2002, an additional isoform, VEGF165b, was identi-
fied which contained part of the 3’ UTR that is now deter-
mined to be exon 8b (Figure 3). Furthermore, recent stud-
ies have demonstrated that the human VEGF165b isoform 
is anti-angiogenic in function and inhibits signal transduc-
tion through KDR (Bates et al. 2002; Woolard et al. 2004). 
Thus, this isoform is inhibitory to the actions of VEGF. Re-
cently several other inhibitory isoforms have been identi-
fied in the human and we have cloned several in both the 
rat and bovine (VEGF165b accession number EU040284; 
VEGF189b accession number EU040285). Therefore, it ap-
pears that for every angiogenic isoform there is a sister in-
hibitory isoform that is formed when exon 8a is replaced 
with exon 8b. (In rodents and cattle the sister inhibitory 
isoform is one amino acid longer.) The primary functions 
of angiogenic VEGF isoforms are to induce endothelial cell 
migration, survival, proliferation and differentiation to ini-
tiate angiogenesis within developing organs and tumors. 
The inhibitory VEGF isoforms appear to modulate these 
functions.
In addition to the multiple VEGF isoforms, two co-re-
ceptors, neuropilin1 (NRP1) and neuropilin2 (NRP2), that 
bind to specific VEGF isoforms (i.e. VEGF164, VEGF188) 
have been identified. The predominant function of NRP1 
appears to be stabilization of VEGF164 binding to KDR 
which augments signal transduction. The two co-recep-
tors can also stabilize binding of VEGF isoforms to FLT1. 
In fact, FLT1 may regulate VEGF actions by tying up NRP 
bound isoforms. While both NRP co-receptors can bind to 
FLT1 it appears that only NRP1 can stabilize signal trans-
duction through KDR. Interestingly, KDR, but not FLT1 is 
expressed during seminiferous cord formation (Bott et al. 
2006) thus the ability of NRP1 to enhance signal transduc-
tion upon binding of VEGF isoforms to KDR may be criti-
cal during testis differentiation.
Figure 3. Exons in VEGF gene that compose each VEGF 
isoform. 
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What Signal Transduction Pathways Does VEGF 
Activate Through KDR and Which Are Critical for  
Testis Cord Formation?
Vascular endothelial growth factor induces the activation 
of several signal transduction pathways upon binding to 
KDR. Of these pathways, Phospholipase C gamma acti-
vates protein kinase C causing activation of Ras or Raf and 
ultimately MAPK and ERK phosphorylation. The result of 
ERK phosphorylation is endothelial cell proliferation (Shu 
et al. 2002). The PI3-kinase pathway has been demonstrated 
to affect migration and permeability through Rac and per-
meability and survival through Akt (Gerber et al. 1998). The 
p38MAPK and FAK pathways are also postulated to affect 
actin reorganization and focal adhesion turnover to influ-
ence migration (Goligorsky et al. 1999). Several of these 
VEGF signal transduction pathways may interact to initiate 
endothelial cell differentiation, migration, proliferation and 
survival. Inhibition of the MAPK pathway affects cord for-
mation (Uzumcu et al. 2002b) in testis organ cultures; how-
ever, PI3-kinase inhibits both seminiferous cord formation 
(Uzumcu et al. 2002b; Bott et al. 2006) and vascular devel-
opment (Bott et al. 2006). Thus, both of these sex-specific 
events, vascular development and cord formation may be 
regulated by multiple growth factors through a similar sig-
nal transduction pathway.
  
  
What specific roles do the VEGF isoforms have in endothelial cell 
migration?
Endothelial cell recruitment and chemoattraction requires 
several different VEGF isoforms to establish a VEGF con-
centration gradient. At least three of the angiogenic VEGF 
isoforms are associated with specific endothelial cell func-
tions (Veikkola and Alitalo 1999). VEGF120, a highly dif-
fusible isoform, recruits endothelial cells into tissue to ini-
tiate the development of vasculogenesis while VEGF164 
can recruit endothelial cells and establish large blood ves-
sels. VEGF188, due to its heparin binding domain, acts 
locally to induce branching of large blood vessels into 
smaller capillaries and the development of capillary beds 
(Grunstein et al. 2000) (Figure 3). Furthermore, these three 
isoforms are thought to establish a VEGF chemoattractant 
gradient to allow for endothelial cell migration. In the tes-
tis, VEGF120, 188 and 164 are present during seminiferous 
cord formation and can develop a viable chemoattractant 
gradient (Bott et al. 2006). In contrast, in the ovary only 
VEGF164 and 120 are present (Pohlmann et al. 2004). The 
absence of the larger VEGF isoforms to anchor the che-
moattractant gradient inhibits endothelial cell migration 
and weakens the attraction to VEGF secreting cells (Ruhr-
berg 2003). Therefore, in the ovary a viable chemoattrac-
tant gradient may not be present contributing to the lack 
of mesonephric cell migration.
VEGF165b is anti-angiogenic and appears to inhibit the 
actions of VEGF164 and to a lesser extent other VEGF iso-
forms. The inhibitory isoform, VEGF165b is expressed in all 
tissues but is down-regulated in prostate tumors (Woolard 
et al. 2004), renal tumors (Bates et al. 2002) and in disorders 
of the eye such as macular degeneration (Perrin et al. 2005). 
The mechanism of differential VEGF isoform expression 
is not known but is likely related to transcriptional and/
or post-transcriptional regulation of the VEGF gene which 
results in different ratios of angiogenic to inhibitory VEGF 
isoforms expressed.
One role of the inhibitory VEGF isoforms may be to in-
hibit the chemoattractant gradient and inhibit endothelial 
cell migration (Bates et al. 2002; Woolard et al. 2004). Our 
laboratory has subcloned and sequenced the rat VEGF165b 
and determined that there is a sex-specific expression of 
VEGF165b (fourfold higher in ovary than testis; unpub-
lished data) during the time endothelial cell migration oc-
curs. Therefore, the VEGF165b isoform may be expressed 
in the ovary to prevent establishment of a chemoattractant 
gradient and migration of endothelial cells from the meso-
nephros into the developing ovary.
    
How are specific VEGF isoform actions regulated?
Neuropilin1, a VEGFA co-receptor, appears to modu-
late VEGFA signal transduction (Klagsbrun and Eich-
mann 2005). Neuropilins were first identified as receptors 
for axon guidance forming complexes with the plexin-
A subfamily to modulate semaphorin signals (Takahashi 
et al. 1998). However, recent studies have identified a role 
for neuropilins in VEGF-dependent angiogenic processes. 
Specifically, NRP1 knockout mice have vasculature, heart 
and neural defects and die at E10.5–12.5 suggesting that 
NRP1 is necessary for normal vascular development (Ka-
wasaki et al. 1999). If NRP1 binds to semaphorin instead of 
VEGF then endothelial cell migration is inhibited (Miao et 
al. 1999). Likewise, if NRP1/VEGF complexes bind to FLT1 
this also may inhibit endothelial cell migration and the de-
velopment of vasculature.
The predominant function of NRP1 appears to be sta-
bilization of VEGFA164 binding to KDR which augments 
signal transduction. The two co-receptors can also stabi-
lize binding of angiogenic VEGFA isoforms to FLT1. Infact, 
FLT1 may regulate angiogenic VEGF actions by enticing 
NRP bound isoforms to bind to this decoy receptor. While 
both NRP co-receptors can bind to FLT1 it appears that 
only NRP1 can stabilize signal transduction through KDR.
Initially, VEGFA isoforms containing exon 7 or a hepa-
rin binding domain (also in exon 6) were thought to bind to 
NRP1. However, there have been recent studies that sug-
gest NRPs (in addition to binding to VEGF164 and 188 that 
contain heparin binding domains) also bind to VEGFA120 
(which does not have a heparin binding domain). Although 
they bind VEGFA120, the interaction does not allow for the 
bridging of the two receptors (NRP1 and KDR) that oc-
cur with VEGF164 or 188. Therefore, the interaction with 
VEGF120 does not appear to stabilize and amplify signal 
transduction which occurs with VEGF164 (Pan et al. 2007).
Exon 8a also appears to be important in binding of NRPs 
to VEGF angiogenic isoforms (Jia et al. 2006). It has been 
demonstrated that inhibitory VEGF isoforms such as 165b 
cannot bind NRPs since exon 8b replaces 8a. Therefore, 
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NRPs can convey angiogenic vs inhibitory isoform speci-
ficity to cells and if NRPs are eliminated from cells then the 
actions of angiogenic isoforms may be impaired.
    
What regulates VEGF gene expression?
Hypoxia (Schweda et al. 2000), oestradiol (Mueller et al. 
2000), progesterone (Mueller et al. 2003), and factors sig-
nalling through the SMAD signal transduction pathway 
(He and Chen 2005) have all been implicated in increased 
or decreased expression of VEGF isoforms. Results from in 
vitro studies (Activin A/B, BMPs, AMH) (Yao et al. 2004) 
and null mice (Inhbb, Follistatin and Wnt4) (Yao et al. 2004, 
2006) suggest that TGF-β family members or proteins that 
inhibit their actions are involved in modulation of vascular 
development in the developing gonad. Interestingly, in the 
zebrafish SMAD response elements regulate VEGF gene ex-
pression (He and Chen 2005). Deletion of either SMAD1 or 
SMAD5 response elements on the zebrafish VEGF promoter 
resulted in either inhibition or enhanced transcription of 
the VEGF gene (He and Chen 2005). Within the murine 
VEGF promoter there are multiple consensus sequences for 
SMAD response elements (AS Cupp, unpublished data). 
Therefore, it is highly possible that growth factors signal-
ling through the SMAD signal transduction pathways alter 
the expression of VEGF and VEGF-signal transduction me-
diators or potentially affect post-translational modification 
of VEGF to allow for different ratios of angiogenic vs inhib-
itory isoforms to be expressed (Figure 2).
    
What Mouse Models Can Be Used to Understand the 
Function of VEGF During Testis Morphogenesis?
Null mutations of VEGF are embryonic lethal with even the 
loss of one allele resulting in embryonic death at E11 dpc 
(Carmeliet et al. 1996; Ferrara et al. 1996). Similarly, homo-
zygous knockouts for either receptor, FLT1 or KDR, die on 
9–10 dpc (Millauer et al. 1994; Hiratsuka et al. 1998). Thus, 
these ubiquitous knockout models prevent us from deter-
mining the role of VEGF in testis morphogenesis and/or 
vascular patterning of the gonad. Overexpression of VEGF 
is equally detrimental to fertility and embryonic viability 
(Miquerol et al. 2000; Huminiecki et al. 2001).
Many conditional mutants have been developed which 
knock out VEGF ubiquitously later in development (in the 
neonate; Gerber et al. 1999) or in specific tissues (i.e. nerves 
in skin (Mukouyama et al. 2005). In these studies VEGF was 
determined to be required for proliferation and survival of 
endothelial cells. The deletion of VEGF in newborn mice in 
every cell of the body resulted in smaller mice that did not 
survive to adulthood. However, if VEGF was knocked out 
later in the fully developed animal there was less of an ef-
fect on growth.
Overexpression of VEGF in transgenic mice results in in-
fertility (Korpelainen et al. 1998). Furthermore, overexpres-
sion of human165b through the MMLV promoter results 
in disruption of mammary gland development, and death 
postnatally in offspring from over-expressing females due 
to malnutrition (Qiu et al. 2007). However, until a testis-
specific knockout mouse is developed it is unclear how re-
moval of Sertoli-cell secretion of VEGF will affect testis de-
velopment and function. Thus, further experiments need to 
be conducted in vivo to demonstrate the role of VEGF on 
sex-specific vascular development, seminiferous cord for-
mation and testis function.
    
Conclusion
Approximately 2 million couples seek treatment for infertil-
ity every year and less than half find successful treatments 
(Carlsen et al. 2005). Infertility problems in at least half of 
these couples are a result of male-related factors that are 
created by testicular dysgenesis. Many of the problems as-
sociated with testicular dysgenesis are proposed to involve 
a disruption in embryonic differentiation of cells within the 
indifferent gonad resulting in altered testicular develop-
ment. Elucidating the factors involved in sex-specific vas-
cular development will allow for a better understanding of 
how transcription factors coordinate regulation of growth 
factors to result in a testis-specific vascular system. Fur-
thermore, delineating the interaction of VEGF angiogenic 
and inhibitory isoforms in sex-specific vascular develop-
ment promises to be an interesting piece in the puzzle of 
gonadal development.
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